Topotecan and Melphalan for Retinoblastoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Chemotherapy Effect
- Retinoblastoma
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Younger than 125 years
- Gender
- Both males and females
Description
To evaluate the effectiveness and complications of topotecan and melphalan for intraocular injection in retinoblastoma patients.
To evaluate the effectiveness and complications of topotecan and melphalan for intraocular injection in retinoblastoma patients.
Tracking Information
- NCT #
- NCT04799002
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Huashen Yang Sun Yat-sen University